Abstract Details

Title Patients Who Received Alemtuzumab in CARE-MS I or II Show a Low Rate of Conversion From Relapsing-Remitting MS to Secondary Progressive MS Through 6 Years

Topic Multiple Sclerosis

Presentation(s) P4 - (-)

Poster/Presentation
Number 407

Background Delaying conversion to SPMS is an important treatment goal in MS. In an MSBase patient cohort (17,356 MS patients; median baseline disease duration 3.8 years; median 5.8-year follow-up), 18% of all patients converted to SPMS using a recently developed SPMS definition based on EDSS scores and relapses. In the CARE-MS studies, EDSS scores were stable/improved with alemtuzumab over 6 years in >75% of patients with active RRMS who were treatment-naive (CARE-MS I; NCT00530348) or had inadequate response (≥1 relapse) to prior therapy (CARE-MS II; NCT00548405), in the absence of continuous treatment (extension study: NCT00930553).

Objective

Design/Methods Patients with active RRMS received 2 courses of alemtuzumab 12 mg (baseline: 5 consecutive days; 12 months later: 3 consecutive days) in CARE-MS I or II, and in the extension as-needed alemtuzumab for relapse or MRI activity, or another disease-modifying therapy (DMT) per investigator discretion. The definition of SPMS onset was as published by Lorscheider et al. (Brain 2016;139:2395-405).

Results Median disease duration at baseline was 1.7 years in CARE-MS I and 3.8 years in CARE-MS II (2.8 pooled). 325/376 (86%) and 344/435 (79%) alemtuzumab-treated patients, respectively, remained on study through Year 6 (669/811 [82%] pooled). Many patients (CARE-MS I: 63%; CARE-MS II: 50%) received no additional treatment in the extension (either alemtuzumab or other DMT). Among alemtuzumab-treated CARE-MS I or II patients, the SPMS definition was met by 4 (1.1%) and 16 (3.7%) patients, respectively, through 6 years (20 [2.5%] pooled).

Conclusions Utilizing an objective definition of SPMS based on the EDSS and relapse data, a very low proportion of alemtuzumab-treated patients from the CARE-MS studies progressed to SPMS.

Authors/Disclosures
	No disclosure on file
Aaron L. Boster, MD (Ohiohealth)	Dr. Boster has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for sanofi. Dr. Boster has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for roche. Dr. Boster has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for novartis. Dr. Boster has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medtronic. Dr. Boster has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Serono. The institution of Dr. Boster has received research support from Sanofi. The institution of Dr. Boster has received research support from Roche.
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Mark S. Freedman, MD, FAAN (University of Ottawa)	Dr. Freedman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Actelion(Janssen/J&J). Dr. Freedman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BiogenIdec. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS/Celgene. Dr. Freedman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for EMD Inc. Dr. Freedman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi-Genzyme. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Freedman has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Actelion (Janssen/J&J). Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Atara Biotherapeutics. Dr. Freedman has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Bayer Healthcare. Dr. Freedman has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for BiogenIdec. Dr. Freedman has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Clene Nanomedicine. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for GRI Bio. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Magenta Therapeutics. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck Serono. Dr. Freedman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Freedman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi Genzyme. Dr. Freedman has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Sanofi Genzyme. Dr. Freedman has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for EMD Serono. The institution of Dr. Freedman has received research support from Sanofi Genzyme.